Aktienanalyse zu Alamar Biosciences Inc (ALMR)ALMRAlamar Biosciences Inc

Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications. It operates in the Healthcare sector.

Alamar Biosciences, Inc. is a good buy right now due to its strong revenue growth, with Q2 2026 revenue reported at $29.4 million, an 82% year-over-year increase, and a gross margin of 60.21%, up from 53.09% in Q2 2025. The stock has also shown a robust performance with a year-to-date change of +80.53%. However, the main risk is the negative net income, which was -$13.19 million in Q2 2026, indicating ongoing losses that investors should monitor closely.